Teva Pharmaceutical reports successful mid-stage trial results for experimental antibody drug TEV '408
Teva Pharmaceutical reported that an experimental antibody drug, TEV '408, succeeded in a mid-stage trial for celiac disease. The drug demonstrated a statistically significant and clinically meaningful ability to prevent gluten-induced intestinal damage over an eight-week period when compared to a placebo.
Show the rest of this summary
Teva Pharmaceutical stated that data from an early-stage trial for vitiligo also suggests the drug has pipeline-in-a-product potential. In a separate development, BioMarin Pharmaceutical settled a patent dispute with Ascendis Pharma regarding the drug Yuviwel, which treats achondroplasia. BioMarin Pharmaceutical received a 20% royalty on net U.S. sales and an 18% royalty on net sales in Europe, Brazil, and South Korea until 2030. Additionally, GSK announced it will move an experimental mRNA vaccine for seasonal influenza into late-stage testing following positive results in a Phase 2 study. The vaccine spurred stronger immune responses against all strains than standard and high-dose flu vaccines. BioNTech announced plans to terminate a Phase 2 study for an experimental mRNA vaccine called autogene cevumeran against colorectal cancer, citing a numerical imbalance in survival between the treatment and placebo groups.